Collegium Pharmaceutical enters the final stretch of Q3 with a fresh bull on the Street and short sellers steadily closing positions — yet the stock trades at $22.78, less than half where analysts think it belongs.
Oppenheimer initiated coverage this morning with an Outperform rating and a $50 price target, adding to a consensus that is uniformly constructive. Every analyst covering COLL carries a Buy or equivalent — five in total — with a mean target near $49. That gap between target and price, at roughly 115%, is extraordinarily wide. It reflects the severity of the August earnings shock: the stock fell 17.5% the day Q2 results crossed the tape and shed another 4% over the five days that followed. Since the print, Truist, Barclays, and Needham have all trimmed targets into the $45-$49 range from the mid-$50s, while Leerink Partners added a fresh Outperform at $45. The directional call is clear — bulls are unified. But their conviction on timing is shakier, with targets drifting lower even as ratings hold.
The core bear case is straightforward: generic competition threatens Collegium's pain franchise, which drives the bulk of revenue. The Azstarys acquisition, meant to diversify the business into ADHD, has underperformed. Bulls counter that the portfolio is more durable than the market is pricing and that the forward earnings trajectory is improving — the 12-month forward EPS growth estimate ranks in the 98th percentile of the ORTEX universe, a figure that looks jarring against a stock down roughly 50% year-to-date. Valuation multiples are deeply compressed. The P/E multiple has declined sharply over the past month and now sits at just 3.3x. EV/EBITDA is below 3.1x. For a profitable specialty pharmaceutical company with five Buy-rated analysts, those are distress-level multiples.
Short sellers appear to be taking note. After peaking above 6.3 million shares in early September, short interest has declined steadily. It now runs at roughly 16.8% of the free float — still elevated, but the one-month change shows an 8.7% reduction in the position. The ORTEX short score has eased from 72.6 in early September to 64.7, consistent with some covering. Borrow conditions remain easy: availability is 443%, meaning there are more than four shares available to lend for every share already borrowed, and cost to borrow is just 0.57%. There is no squeeze mechanics here. Shorts are covering because they want to, not because they're being forced out. Options positioning is similarly calm — the put/call ratio of 0.76 is only marginally above its 20-day average of 0.74 and carries almost no directional signal.
Institutional ownership adds a layer of context. Multiple fund managers have been building positions at these levels. Millennium Management crossed the 5% threshold in August. Principal Global Investors, Janus Henderson, Vanguard Capital Management, and Invesco have all added or newly disclosed stakes above 5% in recent months. BlackRock remains the dominant holder at roughly 16.7% of shares outstanding. No 13D activist filings are on the register — all holdings are passive 13G disclosures, though as-last-disclosed stakes can change without a new filing once a holder drops below the 5% threshold. The pattern of new passive entrants and expanding positions at current levels suggests institutional buyers see the valuation gap as an opportunity rather than a warning.
The next test is the November 5 earnings print. The prior result wiped out 17% of the stock's value in a single session. Whether the accumulation happening now — from passive funds, from covering shorts, and from a freshly initiated analyst — survives another comparable miss is the central question heading into year-end.
See the live data behind this article on ORTEX.
Open COLL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
